Company intelligence / Profile preview
Halo-Bio RNAi Therapeutics
Seattle, Washington, United States
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Halo-Bio RNAi Therapeutics is an early-stage biopharma developing an RNAi platform for multi-gene targeting therapeutics using proprietary MV-RNA triggers and nanoparticle delivery, with preclinical studies in cancer and infectious diseases; clinical results not disclosed as of 2025.
- Therapeutic areas
- OncologyRare DiseasesInfectious Diseases
- Modalities
- Small interfering RNARNA therapyNanoparticle
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Tekmira (licensing of MV-RNA platform)
Beyond the preview
Go deeper on Halo-Bio RNAi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Halo-Bio RNAi Therapeutics.